联合经皮司来吉兰（selegiline）+认知行为治疗不能改善戒烟
2010/11/03
摘要
目的：研究经皮司来吉兰对戒烟的疗效。
设计：成人吸烟者随机分为司来吉兰治疗组（STS）组和安慰剂组，治疗时间为8周。所有参与者均接受认知行为治疗（CBT）。分别在25周和52周进行随访。
研究机构：社区戒烟门诊。参与者为243名成人吸烟者（≥18岁，每日≥10支）。
检测指标：呼出气一氧化碳含量确定7天的点戒断率。
结果：STS的疗效并不优于安慰剂。52周随访显示，女性较男性戒断多（28% vs 16%, P < 0.05）。行为激发（BAS）对治疗反应具有中度作用（P = 0.01）。
结论：虽然经皮司来吉兰治疗对某些低行为激活的吸烟者来说具有选择性作用，但不能有效改善总体戒烟状态。
（林江涛 审校）
Addiction. 2010 Sep;105(9):1660-1668.
Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy
Killen JD, Fortmann SP, Murphy GM Jr, Hayward C, Fong D, Lowenthal K, Bryson SW, Killen DT, Schatzberg AF.
Departments of Medicine and Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
Abstract
Aims To examine the effectiveness of transdermal selegiline for producing cigarette smoking abstinence. Design Adult smokers were randomly assigned to receive selegiline transdermal system (STS) or placebo given for 8 weeks. All participants received cognitive behavior therapy (CBT). Follow-ups were conducted at 25 and 52 weeks. Setting Community smoking cessation clinic. Participants 243 adult smokers (>/=18 years of age; >/=10 cigarettes/day). Measures Expired-air carbon monoxide confirmed 7-day point prevalence abstinence. Findings STS was not superior to placebo. More women than men were abstinent at 52 week follow-up (28% vs 16%, P < 0.05). Behavioral activation (BAS) moderated treatment response (P = 0.01). The survival rate through week 52 for those with high ’drive’ scores on the BAS was 47% if assigned to selegiline and 34% if assigned to placebo. The survival rate for those with low ’drive scores’ on the BAS was 35% if assigned to selegiline compared to 53% if assigned to placebo. Conclusion Transdermal selegiline does not appear generally effective in aiding smoking cessation though there may be a selective effect in those smokers with low ’behavioral activation’.
Addiction. 2010 Sep;105(9):1660-8.
目的：研究经皮司来吉兰对戒烟的疗效。
设计：成人吸烟者随机分为司来吉兰治疗组（STS）组和安慰剂组，治疗时间为8周。所有参与者均接受认知行为治疗（CBT）。分别在25周和52周进行随访。
研究机构：社区戒烟门诊。参与者为243名成人吸烟者（≥18岁，每日≥10支）。
检测指标：呼出气一氧化碳含量确定7天的点戒断率。
结果：STS的疗效并不优于安慰剂。52周随访显示，女性较男性戒断多（28% vs 16%, P < 0.05）。行为激发（BAS）对治疗反应具有中度作用（P = 0.01）。
结论：虽然经皮司来吉兰治疗对某些低行为激活的吸烟者来说具有选择性作用，但不能有效改善总体戒烟状态。
（林江涛 审校）
Addiction. 2010 Sep;105(9):1660-1668.
Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy
Killen JD, Fortmann SP, Murphy GM Jr, Hayward C, Fong D, Lowenthal K, Bryson SW, Killen DT, Schatzberg AF.
Departments of Medicine and Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
Abstract
Aims To examine the effectiveness of transdermal selegiline for producing cigarette smoking abstinence. Design Adult smokers were randomly assigned to receive selegiline transdermal system (STS) or placebo given for 8 weeks. All participants received cognitive behavior therapy (CBT). Follow-ups were conducted at 25 and 52 weeks. Setting Community smoking cessation clinic. Participants 243 adult smokers (>/=18 years of age; >/=10 cigarettes/day). Measures Expired-air carbon monoxide confirmed 7-day point prevalence abstinence. Findings STS was not superior to placebo. More women than men were abstinent at 52 week follow-up (28% vs 16%, P < 0.05). Behavioral activation (BAS) moderated treatment response (P = 0.01). The survival rate through week 52 for those with high ’drive’ scores on the BAS was 47% if assigned to selegiline and 34% if assigned to placebo. The survival rate for those with low ’drive scores’ on the BAS was 35% if assigned to selegiline compared to 53% if assigned to placebo. Conclusion Transdermal selegiline does not appear generally effective in aiding smoking cessation though there may be a selective effect in those smokers with low ’behavioral activation’.
Addiction. 2010 Sep;105(9):1660-8.
上一篇：
在患有勃起功能障碍的中国患者中的戒烟与依从性干预
下一篇：
尼古丁替代治疗戒烟的不良反应：对177390人参与的120个研究进行的系统综述和荟萃分析
